Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $1.86, with 3.21 million shares of worth about $5.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.25% during that period and on October 23, 2024 the price saw a loss of about -4.12%. Currently the company’s common shares owned by public are about 361.49M shares, out of which, 349.07M shares are available for trading.
Stock saw a price change of -2.62% in past 5 days and over the past one month there was a price change of 18.47%. Year-to-date (YTD), LXRX shares are showing a performance of 21.57% which increased to 70.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.92 but also hit the highest price of $3.73 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 2.77 million. The stock is currently trading 6.44% above its 20-day simple moving average (SMA20), while that difference is up 8.98% for SMA50 and it goes to -2.24% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 361.49M outstanding shares and institutions hold larger chunk of about 76.92% of that.
The stock has a current market capitalization of $672.37M and its 3Y-monthly beta is at 1.28. It has posted earnings per share of -$0.77 in the same period. It has Quick Ratio of 11.49 while making debt-to-equity ratio of 0.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 8.59% while standing at 6.20% over the month.
Stock’s fiscal year EPS is expected to rise by 14.05% while it is estimated to increase by 12.42% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 17, 2024 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Leerink Partners stated Lexicon Pharmaceuticals Inc (LXRX) stock as an Outperform in their note to investors on April 30, 2024, suggesting a price target of $5 for the stock. On March 07, 2023, Jefferies Initiated their recommendations, while on August 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $10. Stock get a Neutral rating from JP Morgan on January 29, 2021.
